Cerus (CERS) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cerus (CERS) has outperformed MiMedx Group (MDXG) over the past year, gaining 14.2% versus a loss of 54.9%. Over five years, MDXG leads with a -58.6% price change compared with -73.5% for CERS. MiMedx Group is the larger company by market cap ($445.1 million vs $373.6 million), about 1.2 times the size.
On valuation, MiMedx Group trades at a lower forward P/E (122.0x vs 123.3x for Cerus). MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -6.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERS | MDXG |
|---|---|---|
| Share price | $1.85 | $3.05 |
| Market cap | $373.62M | $445.07M |
| 1-day change | -2.63% | -1.93% |
| YTD return | -10.19% | -54.95% |
| 1-year return | +14.20% | -54.88% |
| 5-year return | -73.50% | -58.62% |
| Forward P/E | 123.33 | 122.00 |
| EPS (TTM) | $-0.04 | $-0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $233.80M | $418.63M |
| Revenue growth (YoY) | +16.13% | +19.99% |
| Net income (latest FY) | $-15.63M | $48.58M |
| Gross margin | — | 82.56% |
| Operating margin | -3.71% | 15.26% |
| Net margin | -6.68% | 11.60% |
| 52-week high | $3.47 | $7.45 |
| 52-week low | $1.59 | $3.03 |
| Distance from 52-week high | -46.69% | -59.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +177.30% | +129.51% |
| Average volume | 2.12M | 1.39M |
| Shares outstanding | 201.95M | 145.93M |
| Employees | 261 | 808 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CERS has outperformed MDXG by 69.1 percentage points over the past year.
- MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Health Care · Medical/Dental Instruments · 261 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
CERS vs MDXG FAQ
Which is bigger, Cerus or MiMedx Group?
MiMedx Group (MDXG) is larger, with a market capitalization of $445.07M compared with $373.62M for Cerus (CERS).
Which stock has performed better over the past year, CERS or MDXG?
CERS returned +14.20% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are Cerus and MiMedx Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.